Further studies determining levels of CYTSA proteins in independent larger cohorts of CRC tissue microarrays with both primary and metastatic tumor samples and correlating CYTSA protein levels to patient survival and other clinical parameters will provide a better understanding of the effects of CYTSA alterations on CRC tumor growth and metastasis. This evidence concerns the gene SPECC1L and colorectal carcinoma.